Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian R Murphy

Showing results (81-90 of 122) with videos related to

Pageof 13
Sort By:
Journal of Virology|February 4, 2011
Identification of human parainfluenza virus type 2 (HPIV-2) V protein amino acid residues that reduce binding of V to MDA5 and attenuate HPIV-2 replication in nonhuman primatesAnne Schaap-Nutt, Caraline Higgins, Emerito Amaro-Carambot, et al.
The Journal of Infectious Diseases|February 3, 2005
rDEN4delta30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteersAnna P Durbin, Stephen S Whitehead, Julie McArthur, et al.
Human Vaccines|November 16, 2006
rDEN2/4Delta30(ME), a live attenuated chimeric dengue serotype 2 vaccine is safe and highly immunogenic in healthy dengue-naïve adultsAnna P Durbin, Julie H McArthur, Jennifer A Marron, et al.
The Journal of Infectious Diseases|August 10, 2005
A hexavalent human rotavirus-bovine rotavirus (UK) reassortant vaccine designed for use in developing countries and delivered in a schedule with the potential to eliminate the risk of intussusceptionAlbert Z Kapikian, Lone Simonsen, Timo Vesikari, et al.
Vaccine|January 22, 2008
Evaluation of the Langat/dengue 4 chimeric virus as a live attenuated tick-borne encephalitis vaccine for safety and immunogenicity in healthy adult volunteersPeter F Wright, Sharon Ankrah, Susan E Henderson, et al.
Journal of Virology|November 16, 2004
Recombinant human Metapneumovirus lacking the small hydrophobic SH and/or attachment G glycoprotein: deletion of G yields a promising vaccine candidateStéphane Biacchesi, Mario H Skiadopoulos, Lijuan Yang, et al.
Plos Neglected Tropical Diseases|August 11, 2011
A single dose of the DENV-1 candidate vaccine rDEN1Δ30 is strongly immunogenic and induces resistance to a second dose in a randomized trialAnna P Durbin, Stephen S Whitehead, Donna Shaffer, et al.
Vaccine|January 15, 2008
Dengue virus type 3 vaccine candidates generated by introduction of deletions in the 3' untranslated region (3'-UTR) or by exchange of the DENV-3 3'-UTR with that of DENV-4Joseph E Blaney, Neeraj S Sathe, Laura Goddard, et al.
Journal of Virology|August 24, 2007
Immunization of primates with a Newcastle disease virus-vectored vaccine via the respiratory tract induces a high titer of serum neutralizing antibodies against highly pathogenic avian influenza virusJoshua M DiNapoli, Lijuan Yang, Amorsolo Suguitan, et al.
Vaccine|January 27, 2009
Delivery to the lower respiratory tract is required for effective immunization with Newcastle disease virus-vectored vaccines intended for humansJoshua M DiNapoli, Jerrold M Ward, Lily Cheng, et al.
Pageof 13

Showing results (81-90 of 122) with videos related to

Sort By:
Pageof 13
Journal of Virology|February 4, 2011
Identification of human parainfluenza virus type 2 (HPIV-2) V protein amino acid residues that reduce binding of V to MDA5 and attenuate HPIV-2 replication in nonhuman primatesAnne Schaap-Nutt, Caraline Higgins, Emerito Amaro-Carambot, et al.
The Journal of Infectious Diseases|February 3, 2005
rDEN4delta30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteersAnna P Durbin, Stephen S Whitehead, Julie McArthur, et al.
Human Vaccines|November 16, 2006
rDEN2/4Delta30(ME), a live attenuated chimeric dengue serotype 2 vaccine is safe and highly immunogenic in healthy dengue-naïve adultsAnna P Durbin, Julie H McArthur, Jennifer A Marron, et al.
The Journal of Infectious Diseases|August 10, 2005
A hexavalent human rotavirus-bovine rotavirus (UK) reassortant vaccine designed for use in developing countries and delivered in a schedule with the potential to eliminate the risk of intussusceptionAlbert Z Kapikian, Lone Simonsen, Timo Vesikari, et al.
Vaccine|January 22, 2008
Evaluation of the Langat/dengue 4 chimeric virus as a live attenuated tick-borne encephalitis vaccine for safety and immunogenicity in healthy adult volunteersPeter F Wright, Sharon Ankrah, Susan E Henderson, et al.
Journal of Virology|November 16, 2004
Recombinant human Metapneumovirus lacking the small hydrophobic SH and/or attachment G glycoprotein: deletion of G yields a promising vaccine candidateStéphane Biacchesi, Mario H Skiadopoulos, Lijuan Yang, et al.
Plos Neglected Tropical Diseases|August 11, 2011
A single dose of the DENV-1 candidate vaccine rDEN1Δ30 is strongly immunogenic and induces resistance to a second dose in a randomized trialAnna P Durbin, Stephen S Whitehead, Donna Shaffer, et al.
Vaccine|January 15, 2008
Dengue virus type 3 vaccine candidates generated by introduction of deletions in the 3' untranslated region (3'-UTR) or by exchange of the DENV-3 3'-UTR with that of DENV-4Joseph E Blaney, Neeraj S Sathe, Laura Goddard, et al.
Journal of Virology|August 24, 2007
Immunization of primates with a Newcastle disease virus-vectored vaccine via the respiratory tract induces a high titer of serum neutralizing antibodies against highly pathogenic avian influenza virusJoshua M DiNapoli, Lijuan Yang, Amorsolo Suguitan, et al.
Vaccine|January 27, 2009
Delivery to the lower respiratory tract is required for effective immunization with Newcastle disease virus-vectored vaccines intended for humansJoshua M DiNapoli, Jerrold M Ward, Lily Cheng, et al.
Pageof 13